

1 BONNETT, FAIRBOURN, FRIEDMAN
 & BALINT, P.C.
 2 ELAINE A. RYAN (*To be Admitted Pro Hac Vice*)
 PATRICIA N. SYVERSON (CA SBN 203111)
 3 LINDSEY M. GOMEZ-GRAY (*To be Admitted Pro Hac Vice*)
 2325 E. Camelback Rd. Suite 300
 4 Phoenix, AZ 85016
eryan@bffb.com
psyverson@bffb.com
lgomez-gray@bffb.com
 6 Telephone: (602) 274-1100

7 BONNETT, FAIRBOURN, FRIEDMAN
 & BALINT, P.C.
 8 Manfred P. Muecke (CA SBN 222893)
 600 W. Broadway, Suite 900
 9 San Diego, California 92101
mmuecke@bffb.com
 10 Telephone: (619) 756-7748

11 STEWART M. WELTMAN, LLC
 Stewart M. Weltman (*To be Admitted Pro Hac Vice*)
 12 53 W. Jackson Suite 364
 Chicago, IL 60604
sweltman@weltmanlawfirm.com
 13 Telephone: (312) 588-5033

14 Attorneys for Plaintiff

15 UNITED STATES DISTRICT COURT

16 NORTHERN DISTRICT OF CALIFORNIA

17
 18
 19 PHILLIP RACIES, On Behalf of
 Himself and All Others Similarly
 20 Situated,

21 Plaintiff,

22 v.

23
 24 QUINCY BIOSCIENCE, LLC, a
 25 Wisconsin limited liability company,

26 Defendant.

Case No.:

CLASS ACTION COMPLAINT FOR:

1. VIOLATION OF THE UNFAIR COMPETITION LAW, Business and Professions Code §17200 *et seq.*; and
2. VIOLATION OF THE CONSUMERS LEGAL REMEDIES ACT, Civil Code §1750 *et seq.*

27 DEMAND FOR JURY TRIAL

1 Plaintiff Phillip Racies brings this action on behalf of himself and all others
2 similarly situated against Defendant Quincy Bioscience, LLC and states:

3 **NATURE OF ACTION**

4 1. Defendant manufactures, markets, sells and distributes Prevagen, a
5 purported brain health supplement made with the protein apoaequorin.¹ As its
6 Wikipedia cite notes, apoaequorin is used as a light emitting marker “in a broad
7 range of biological research work at the cellular level.” Through an extensive,
8 widespread, comprehensive and uniform nationwide marketing campaign, and on
9 the front of each and every Product package, where it cannot be missed by
10 consumers, Defendant represents: (1) that the Products are “clinically tested” to
11 “improve[] memory” and “support[]: healthy brain function, sharper mind, and
12 clearer thinking”; and (2) that Prevagen is “clinically tested” to “improve memory
13 within 90 days” (collectively, “the brain function and memory representations”).
14 Defendant’s brain function and memory representations are false, misleading and
15 reasonably likely to deceive the public.

16 2. Plaintiff and his counsel have retained one of the world’s foremost
17 experts in brain chemistry and an expert in the field regarding whether and how
18 substances may or may not affect brain function and memory.

19 3. He has evaluated the ingredients in Prevagen, along with reviewing the
20 summaries of purported² clinical studies that Defendant provides on its Product
21 packaging and on its website. He has concluded that: (1) Prevagen cannot work as
22 represented because apoaequorin, the only purported active ingredient in Prevagen,
23

24 _____
25 ¹ Prevagen is available in regular strength (10 mg. apoaequorin), extra strength (20 mg.
26 apoaequorin) and mixed berry chewable forms (10 mg. apoaequorin) (collectively “Prevagen” or
27 “the Products”). Plaintiff reserves the right to add additional products upon completion of
28 discovery.

² They are “purported” because there is no evidence that these studies were actually conducted,
properly conducted or that the summaries accurately reflect the actual results of the purported
studies.

1 is completely destroyed by the digestive system and transformed into common
2 amino acids no different than those derived from other common food products such
3 as chicken, cold cuts, hamburgers, etc.; (2) the average daily diet contains about 75
4 grams of protein, contains all the required amino acids, and has about 7,500 times
5 more amino acids than Prevagen (10 mg or 0.01 grams) and, as a result, any amino
6 acids derived from the digestion of Prevagen would be massively diluted and could
7 have no measurable effect on the brain; (3) ingestion of Prevagen cannot and does
8 not have any effect on brain function or memory; and (4) the three summaries of
9 purported clinical studies, one on the Product packaging and two on Defendant's
10 websites, apart from not being clear that these studies exist at all, are, on their face,
11 so seriously flawed that they demonstrate nothing regarding Prevagen. As a result,
12 Defendant's citation to these purported studies, particularly the one summarized on
13 the Product packaging, is a separate and distinct misrepresentation – they are cited
14 as purportedly demonstrating efficacy when, in fact, they demonstrate nothing and
15 could not since, as a matter of body chemistry, Prevagen can do nothing to enhance
16 brain function or memory.

17 4. The Prevagen packaging states that the Product is “clinically tested” to
18 provide the brain function and memory benefits. By stating that the Product is
19 clinically tested, Defendant is representing to consumers that credible scientific
20 evidence supports Defendant's claim that the Product provides the brain function
21 and memory benefits.

22 5. Reasonable consumers understand “clinically tested” to mean that
23 there is competent and reliable scientific support for the brain function and memory
24 benefit representations. However, there can never be any competent and reliable
25 scientific evidence supporting Defendant's brain function and memory
26 representations, because, as alleged herein, the apoaequorin in Defendant's Product
27 is fully digested, broken down into common amino acids and is massively diluted
28

1 before entering the bloodstream. Furthermore, for at least the last 50 years, the
2 universally accepted form of scientific evidence recognized by experts in the field
3 for determining whether a substance provides any human health benefit is by
4 demonstrating its value over placebo through high quality and well-conducted
5 randomized controlled clinical trials (“RCTs”). Also, it is generally recognized that
6 RCTs that are of sufficient quality to be relied upon for reaching efficacy
7 conclusions should be subjected to a peer review process and published in a peer
8 reviewed journal.

9 6. A properly conducted RCT has a detailed protocol that describes how
10 the study is going to be conducted; is double blinded with a description of the
11 blinding procedures; is randomized with a description of the randomization
12 procedure; at a minimum, has primary endpoints that are described in detail;
13 contains a report section discussing all of the results; has a complete and validly
14 performed statistical analysis comparing the active ingredient to placebo; and has a
15 conclusions section that describes the results and how the active ingredient
16 compares to placebo for the previously described endpoints. On the packaging of
17 Defendant’s Product a purported study is summarized. It is a purported study
18 because, other than the grossly simplified, and thus unreliable, results summarized
19 on the packaging, there is absolutely no evidence in the public record that this study
20 was ever performed. A search of *clinicaltrials.gov* where RCTs must be registered
21 to be considered for publication in a peer reviewed journal shows that no RCT
22 involving apoaequorin and brain function or memory was registered. Similarly, the
23 summary on the packaging contains no identifying information such that it is not
24 even clear that the study exists. There is no author identified, no title given to the
25 study and no publication identified where it may have been published. There is
26 nothing in the public record. For example, when the word apoaequorin is searched
27 in Pub-Med, a website maintained by the NIH which contains over 24 million
28

1 published articles, there are 150 citations that result – none of them are studies of
2 apoaequorin and brain function or memory in humans.³ In fact, when
3 “apoaequorin” and “memory” are searched the results contain two reports – one on
4 fly brains regarding the use of apoaequorin for imaging purposes and another an in
5 vitro study of pools of cells.⁴ As such, it is not possible to determine, at least from
6 the label, whether the study exists and even if it does, whether it was properly
7 conducted and properly analyzed. But, even if such a study were conducted,
8 because apoaequorin is completely digested, changed into common amino acids and
9 massively diluted by the far larger quantity of amino acids derived from the average
10 daily diet, there is no possible manner in which Prevagen could have any effect on
11 brain function or memory.

12 7. For the same reasons, the two abstracts/summaries of purported studies
13 purportedly conducted by Defendant summarized on Defendant’s website are not
14 competent and reliable scientific “studies.”

15 8. Defendant’s brain function and memory representations are also
16 unlawful. Prevagen is a dietary supplement. 21 U.S.C. § 321(g)(d). Dietary
17 supplements are regulated under the Dietary Supplement Health and Education Act
18 of 1994 (DSHEA). FDA approval is not required before producing or selling a
19 dietary supplement. However, all health benefit claims on the product package and
20 label must be truthful and not misleading. With regard to each of the
21 representations Defendant makes about Prevagen, this means that Defendant is
22 required to make sure they are truthful and not misleading.

23 9. In order to be truthful and not misleading, dietary supplement health
24 benefit claims must be substantiated by competent and reliable scientific evidence.
25 21 U.S.C. §321(r)(6)(b); Guidance for Industry: Substantiation for Dietary

26 _____
27 ³ <http://www.ncbi.nlm.nih.gov/pubmed/?term=Apoaequorin>

28 ⁴ <http://www.ncbi.nlm.nih.gov/pubmed/?term=apoaequorin+and+memory>

1 Supplement Claims Made Under Section 403(r) (6) of the Federal Food, Drug, and
2 Cosmetic Act (“FDA Guidance of Industry”), Ex. A.

3 10. Under DSHEA, competent and reliable scientific evidence is defined
4 as: “tests, analyses, research, studies, or other evidence based on the expertise of
5 professionals in the relevant area that has been conducted and evaluated in an
6 objective manner by persons qualified to do so, using procedures generally
7 accepted in the profession to yield accurate and reliable results.” FDA Guidance of
8 Industry, Ex. A.

9 11. Plaintiff’s retained expert in brain chemistry and whether and how
10 substances may or may not affect brain function and memory, as well as other
11 experts in these fields, deem the only credible scientific evidence to substantiate
12 human health benefit claims, such as those at issue here, is evidence from high
13 quality RCTs (hereafter “competent and reliable evidence”). No such RCTs exist to
14 substantiate the brain function and memory benefits as the labeling represents that
15 PrevaGen provides.

16 12. Because there is no competent and reliable evidence that PrevaGen
17 provides brain function and memory benefits, Defendant is selling a dietary
18 supplement in violation of federal law, DSHEA, and California’s Sherman Act.

19 13. Defendant has employed numerous media to convey its uniform,
20 deceptive brain function and memory representations to consumers, including
21 magazines, newspapers, the internet, social media websites, and, importantly, on
22 the front of the PrevaGen packaging and labeling where it cannot be missed by
23 consumers. The only reason a consumer would purchase PrevaGen is to obtain the
24 advertised brain function and memory benefits, which it does not provide.
25 PrevaGen is a singular purpose product – its only purported benefit is to enhance
26 brain function and memory which it does not and cannot do.

27 14. As a result of Defendant’s deceptive and unlawful brain function and
28

1 memory representations, consumers – including Plaintiff and members of the
2 proposed Class – have purchased Products that do not perform as advertised.

3 15. Plaintiff brings this action on behalf of himself and other similarly
4 situated consumers who purchased Prevagen, to halt the dissemination of this false,
5 misleading and deceptive advertising message, correct the false and misleading
6 perception it has created in the minds of consumers, and obtain redress for those
7 who have purchased Prevagen. Based on violations of state unfair competition laws
8 (detailed below), Plaintiff seeks injunctive and restitutionary relief for consumers
9 who purchased Prevagen.

10 16. Plaintiff also brings this action on behalf of himself and other similarly
11 situated California consumers who have purchased Prevagen under the “unlawful”
12 prong of the UCL. Plaintiff seeks to halt Defendant’s unlawful sale of Prevagen in
13 violation of applicable FDA law and regulations and California’s Sherman Act and
14 also seeks full restitution of Plaintiff’s and other California consumers’ full
15 purchase price.

16 **JURISDICTION AND VENUE**

17 17. This Court has original jurisdiction pursuant to 28 U.S.C. §1332(d)(2).
18 The matter in controversy, exclusive of interest and costs, exceeds the sum or value
19 of \$5,000,000 and is a class action in which there are in excess of 100 class
20 members and some members of the Class are citizens of a state different from
21 Defendant.

22 18. This Court has personal jurisdiction over Defendant because
23 Defendant is authorized to conduct and does business in California, including this
24 District. Defendant marketed, promoted, distributed, and sold Prevagen in
25 California and Defendant has sufficient minimum contacts with this State and/or
26 sufficiently availed itself of the markets in this State through its promotion, sales,
27 distribution and marketing within this State, including this District, to render the
28

1 exercise of jurisdiction by this Court permissible.

2 19. Venue is proper in this Court pursuant to 28 U.S.C. §§1391(a) and (b)
3 because a substantial part of the events giving rise to Plaintiff's claims occurred
4 while he resided in this judicial district. Venue is also proper under 18 U.S.C.
5 §1965(a) because Defendant transacts substantial business in this District.

6 **PARTIES**

7 20. During the relevant time period, Plaintiff Phillip Racies resided in
8 Petaluma, California. On September 25, 2014, Plaintiff Racies was exposed to and
9 saw Defendant's brain function and memory representations by reading the
10 Prevagen Regular Strength label. Plaintiff Racies purchased and consumed
11 Prevagen Regular Strength at a Walgreens in San Rafael, California in reliance on
12 Defendant's material brain function and memory representations. He paid
13 approximately \$27.99 for the Product. The Prevagen Regular Strength product
14 Plaintiff Racies purchased did not and could not improve memory or support
15 healthy brain function as represented. As a result, Plaintiff Racies suffered injury in
16 fact and lost money. Had Plaintiff Racies known the truth about Defendant's
17 misrepresentations, he would not have purchased Prevagen. Furthermore, Plaintiff
18 was injured when he was induced to purchase a product that but for Defendant's
19 unlawful sale of the Product would not be available for purchase.

20 21. Defendant Quincy Bioscience, LLC is a limited liability company
21 organized and existing under the laws of the state of Wisconsin. Quincy
22 Bioscience, LLC's headquarters is at 301 South Westfield Road, Suite 200, in
23 Madison, Wisconsin. The sole member of Quincy Bioscience, LLC is Quincy
24 Bioscience Holding Company, Inc. Quincy Bioscience Holding Company, Inc. is a
25 Wisconsin corporation. Defendant Quincy Bioscience, LLC is therefore a citizen of
26 Wisconsin. Defendant Quincy Bioscience, LLC manufactures, advertises markets,
27 distributes, and/or sells Prevagen to tens of thousands of consumers in California


1 and throughout the United States

2 **FACTUAL ALLEGATIONS**

3 ***Prevagen***

4 22. Since at least the fall of 2007, Defendant has manufactured,
5 distributed, marketed and sold Prevagen. The Products are marketed as a
6 supplement with the singular purpose of providing key brain health benefits,
7 including improving age-related memory loss.

8 23. Prevagen is sold in virtually every major food, drug, and mass retail
9 outlet in the country. It is also sold on-line at Defendant's website. Prevagen is
10 available in regular strength, extra strength and mixed berry flavor chewable forms.
11 The regular strength and mixed berry flavor products contain 10 mg of apoaequorin
12 per serving, while the extra strength product contains 20 mg of apoaequorin per
13 serving. A 30-count bottle of Prevagen retails for approximately \$28.00 - \$40.00.
14 The following are screen shots of the Products:



24 24. Throughout the relevant time period, Defendant has consistently
25 conveyed the message to consumers throughout the United States, including
26 California, that Prevagen is “clinically tested” to “improve[] memory” and
27

1 “support[]: healthy brain function, shaper mind, and clearer thinking” and is
2 “clinically tested” to “improve memory within 90 days” simply by taking the
3 recommended daily dosage. It does not. Defendant’s brain function and memory
4 representations are false, misleading and deceptive.

5 25. Despite the evidence the Prevagen does not and cannot improve
6 memory or support brain function, sharper mind or clearer thinking, each and every
7 Product package and label repeatedly emphasizes that Prevagen is “clinically
8 tested” to “improve[] memory” and “support[]: healthy brain function, shaper
9 mind, and clearer thinking” and is “clinically tested” to “improve memory within
10 90 days”. Each and every consumer who purchases these Products is exposed to
11 the deceptive brain function and memory representations, which appear
12 prominently and conspicuously on the front and/or back of each Prevagen box as
13 follows:



1 ***Defendant is Unlawfully Selling Prevacen in Violation of Federal and State Law***

2 28. Prevacen is a dietary supplement and governed by DSHEA.

3 29. DSHEA permits the makers of dietary supplements to make claims as
4 to how their supplement affects the structure or function of the body without
5 obtaining prior FDA approval provided certain requirements are met. 21 U.S.C.
6 §§342, 343. One of these requirements is that the manufacturer must have
7 substantiation that the claims are truthful and not misleading. 21 U.S.C.
8 §343(r)(6)(B).

9 30. California's Sherman Food, Drug, and Cosmetic Law (“Sherman Act”)
10 (California’s Health & Safety Code §§109875, et. seq.), parallels the FDCA in
11 material part and adopts the Federal requirements for dietary supplements,
12 including that dietary supplement claims be made in accordance with Section
13 403(r)(6) of the FDCA. Cal. Health & Safety Code § 110100(a).

14 31. The FDA has adopted the FTC’s substantiation standard of “competent
15 and reliable scientific evidence” for dietary supplements as described above.

16 32. Competent and reliable scientific evidence is defined as: “tests,
17 analyses, research, studies, or other evidence based on the expertise of professionals
18 in the relevant area that has been conducted and evaluated in an objective manner
19 by persons qualified to do so, using procedures generally accepted in the profession
20 to yield accurate and reliable results.” FDA Guidance of Industry, Ex. A. For
21 products such as Prevacen, adequate substantiation, as required by experts in the
22 relevant area, consists of high quality RCTs – particularly when representations
23 regarding health affects is the subject matter.

24 33. There are no reliable or high quality RCTs substantiating any of the
25 representations made by Defendant about Prevacen.

26 34. By selling Prevacen without the prerequisite competent and reliable
27 scientific evidence/substantiation for these representations, Defendant has violated

1 DSHEA and the Sherman Act.

2 ***The Impact of Defendant's Wrongful Conduct***

3 35. Plaintiff and Class members have been and will continue to be
4 deceived or misled by Defendant's deceptive brain function and memory
5 representations. Plaintiff and the Class members have been damaged in their
6 purchases of these Products and have been deceived into purchasing Products that
7 they believed, based on Defendant's representations, improved memory and
8 supported brain function, sharper mind and clearer thinking, when, in fact, they do
9 not.

10 **CLASS DEFINITION AND ALLEGATIONS**

11 36. Plaintiff brings this action on behalf of himself and all other similarly
12 situated Class members pursuant to Rule 23(a), (b)(2) and (b)(3) of the Federal
13 Rules of Civil Procedure and seeks certification of the following Class against
14 Defendant for violations of California state laws and/or similar laws in other states:

15 **Multi-State Class Action**

16 All consumers who, within the applicable statute of
17 limitations period, purchased Prevacen in California,
18 Florida, Illinois, Massachusetts, Michigan, Minnesota,
Missouri, New Jersey, New York, and Washington until the
date notice is disseminated.

19 Excluded from this Class are Defendant and its officers,
20 directors and employees and those who purchased Prevacen
for the purpose of resale.

21 37. Alternatively, Plaintiff brings this action on behalf of himself and all
22 other similarly situated California consumers pursuant to Rule 23(a), (b)(2) and
23 (b)(3) of the Federal Rules of Civil Procedure and seeks certification of the
24 following Class:

25 **California-Only Class Action**

26 All California consumers who, within the applicable
27 statute of limitations, purchased Prevacen until the date
notice is disseminated.

1 Excluded from this Class are Defendant and its officers,
2 directors and employees, and those who purchased
3 PrevaGen for the purpose of resale.

4 38. **Numerosity.** The members of the Class are so numerous that joinder
5 of all members of the Class is impracticable. Plaintiff is informed and believes that
6 the proposed Class contains thousands of purchasers of PrevaGen who have been
7 damaged by Defendant's conduct as alleged herein. The precise number of Class
8 members is unknown to Plaintiff.

9 39. **Existence and Predominance of Common Questions of Law and**
10 **Fact.** This action involves common questions of law and fact, which predominate
11 over any questions affecting individual Class members. These common legal and
12 factual questions include, but are not limited to, the following:

- 13 (a) whether Defendant's representations discussed above are misleading,
14 or objectively reasonably likely to deceive;
- 15 (b) whether Defendant's alleged conduct is unlawful;
- 16 (c) whether the alleged conduct constitutes violations of the laws asserted;
- 17 (d) whether Defendant engaged in false or misleading advertising; and
- 18 (e) whether Plaintiff and Class members are entitled to other appropriate
19 remedies, including restitution, corrective advertising and injunctive relief.

20 40. **Typicality.** Plaintiff's claims are typical of the claims of the members
21 of the Class because, *inter alia*, all Class members were injured through the
22 uniform misconduct described above and were subject to Defendant's deceptive
23 brain function and memory representations that accompanied each and every bottle
24 of PrevaGen. Plaintiff is also advancing the same claims and legal theories on
25 behalf of himself and all members of the Class.

26 41. **Adequacy of Representation.** Plaintiff will fairly and adequately
27 protect the interests of the members of the Class. Plaintiff has retained counsel
28 experienced in complex consumer class action litigation, and Plaintiff intends to

1 prosecute this action vigorously. Plaintiff has no adverse or antagonistic interests
2 to those of the Class.

3 42. **Superiority.** A class action is superior to all other available means for
4 the fair and efficient adjudication of this controversy. The damages or other
5 financial detriment suffered by individual Class members is relatively small
6 compared to the burden and expense that would be entailed by individual litigation
7 of their claims against Defendant. It would thus be virtually impossible for
8 members of the Class, on an individual basis, to obtain effective redress for the
9 wrongs done to them. Furthermore, even if Class members could afford such
10 individualized litigation, the court system could not. Individualized litigation
11 would create the danger of inconsistent or contradictory judgments arising from the
12 same set of facts. Individualized litigation would also increase the delay and
13 expense to all parties and the court system from the issues raised by this action. By
14 contrast, the class action device provides the benefits of adjudication of these issues
15 in a single proceeding, economies of scale, and comprehensive supervision by a
16 single court, and presents no unusual management difficulties under the
17 circumstances here.

18 43. Plaintiff seeks preliminary and permanent injunctive and equitable
19 relief on behalf of the entire Class, on grounds generally applicable to the entire
20 Class, to enjoin and prevent Defendant from engaging in the acts described, and
21 requiring Defendant to provide full restitution to Plaintiff and Class members.

22 44. Unless a Class is certified, Defendant will retain monies received as a
23 result of its conduct that were taken from Plaintiff and Class members. Unless a
24 Class-wide injunction is issued, Defendant will continue to commit the violations
25 alleged, and the members of the Class and the general public will continue to be
26 deceived.

27 45. Defendant has acted and refused to act on grounds generally applicable
28

1 to the Class, making appropriate final injunctive relief with respect to the Class as a
2 whole.

3
4 **COUNT I**
5 **Violation of Business & Professions Code §17200, *et seq.***
6 **Unlawful Business Acts and Practices**
7 **(On Behalf of the California-Only Class)**

8 46. Plaintiff repeats and re-alleges the allegations contained in the
9 paragraphs above, as if fully set forth herein.

10 47. Plaintiff brings this claim individually and on behalf of the California-
11 Only Class.

12 48. The Unfair Competition Law, Business & Professions Code §17200, *et*
13 *seq.* (“UCL”), prohibits any “unlawful” business act or practice.

14 49. As alleged herein, Defendant engaged in illegal conduct by unlawfully
15 making the representations set forth above. Because Defendant did not have
16 adequate substantiation that these representations were truthful and not misleading
17 Defendant has committed unlawful business practices by violating California’s
18 Sherman Food, Drug and Cosmetic Law, California’s Health & Safety Code §§
19 109875, *et seq.* and the Food Drug and Cosmetic Act, 21 U.S.C. §§ 301, *et seq.*
20 Plaintiff and the California-Only Class reserve the right to allege other violations of
21 law, which constitute other unlawful business acts or practices. Such conduct is
22 ongoing and continues to this date.

23 50. Plaintiff and the California-Only Class suffered “injury in
24 fact”/economic loss by spending money on a Product that, but for Defendant’s
25 illegal conduct, would not have been on the market.

26 51. The FDA and Sherman Act misbranding/consumer protections are
27 intended to ensure that any claims made about dietary supplements, as defined
28 under the FDA law and regulations, to the consuming public (e.g., sold to Plaintiff

1 and the California-Only Class), are truthful and not misleading.

2 52. The UCL unlawful prong is intended to hold a defendant who violates
3 this prong accountable for its violations by, among other things, paying full
4 compensation to purchasers who have purchased the illegally sold products.

5 53. But for Defendant unlawfully selling Prevagen, Plaintiff and the
6 California Class would never have purchased the illegal Products. As result of
7 Defendant's illegal conduct, Plaintiff and the California-Only Class have suffered
8 injury/economic loss and are entitled to a full refund of their purchase price. Unless
9 restrained and enjoined, Defendant will continue to engage in the illegal sale of the
10 Products. Accordingly, injunctive relief is appropriate.

11 54. Plaintiff, on behalf of himself, all other similarly situated California
12 consumers, and the general public, seeks restitution of all money paid for
13 Defendant's illegally sold Products, an injunction prohibiting Defendant from
14 continuing to sell the Products without adequate substantiation, corrective
15 advertising and all other relief this Court deems appropriate, consistent with
16 Business & Professions Code §17203.

17 **COUNT II**

18 **Violation of Business & Professions Code §17200, *et seq.***
19 **Fraudulent Business Acts and Practices**
20 **(On Behalf of the Multi-State or California-Only Class)**

21 55. Plaintiff repeats and re-alleges the allegations contained in the
22 paragraphs above, as if fully set forth herein.

23 56. Plaintiff brings this claim individually and on behalf of the Class.

24 57. As alleged herein, Plaintiff has suffered injury in fact and lost money
25 or property as a result of Defendant's conduct because he purchased Prevagen in
26 reliance on Defendant's claim that the Product would provide brain function and
27 memory benefits, but did not receive a Product that provides these benefits.

1 58. The Unfair Competition Law, Business & Professions Code §17200, et
2 seq. (“UCL”), and similar laws in the other class states, prohibits any “fraudulent”
3 business act or practice and any false or misleading advertising.

4 59. In the course of conducting business, Defendant committed
5 “fraudulent business act[s] or practices” and false or misleading advertising by,
6 *inter alia*, making the brain function and memory representations (which also
7 constitutes advertising within the meaning of §17200) regarding the Products in its
8 advertising campaign, including the Products’ packaging, as set forth more fully
9 herein.

10 60. Defendant’s actions, claims and misleading statements, as more fully
11 set forth above, are false, misleading and/or likely to deceive the consuming public
12 within the meaning of Business & Professions Code §17200, et seq.

13 61. Plaintiff and other members of the Class have in fact been deceived as
14 a result of their reliance on Defendant’s material brain function and memory
15 representations. Plaintiff and the other Class members have suffered injury in fact
16 and lost money as a result of their purchase(s) of Defendant’s Products which do
17 not provide brain function or memory benefits.

18 62. Unless restrained and enjoined, Defendant will continue to engage in
19 the above-described conduct. Accordingly, injunctive relief is appropriate.

20 63. Plaintiff, on behalf of himself, all others similarly situated, and the
21 general public, seeks restitution of all money obtained from Plaintiff and the
22 members of the Class collected as a result of unfair competition, an injunction
23 prohibiting Defendant from continuing such practices, corrective advertising and all
24 other relief this Court deems appropriate, consistent with Business & Professions
25 Code §17203.

26 ///

27 ///

COUNT III

**Violations of the Consumers Legal Remedies Act – Civil Code §1750 *et seq.*
(On Behalf of the California-Only Class)**

64. Plaintiff repeats and re-alleges the allegations contained in the paragraphs above, as if fully set forth herein.

65. Plaintiff brings this claim individually and on behalf of the California-Only Class.

66. This cause of action is brought pursuant to the Consumers Legal Remedies Act, California Civil Code §1750, *et seq.* (the “Act”).

67. Plaintiff is a consumer as defined by California Civil Code §1761(d). PrevaGen is a “good” within the meaning of the Act.

68. Defendant violated and continues to violate the Act by engaging in the following practices proscribed by California Civil Code §1770(a) in transactions with Plaintiff and the California-Only Class which were intended to result in, and did result in, the sale of PrevaGen:

(5) Representing that [PrevaGen has] . . . approval, characteristics, . . . uses [and] benefits . . . which [it does] not have

* * *

(7) Representing that [PrevaGen is] of a particular standard, quality or grade . . . if [it is] of another.

* * *

(9) Advertising goods . . . with intent not to sell them as advertised.

* * *

(16) Representing that [PrevaGen has] been supplied in accordance with a previous representation when [it has] not.

69. Pursuant to California Civil Code §1782(d), Plaintiff and the California-Only Class seek a Court order enjoining the above-described wrongful

1 acts and practices of Defendant and for restitution and disgorgement.

2 70. Pursuant to §1782 of the Act, Plaintiff notified Defendant in writing by
3 certified mail of the particular violations of §1770 of the Act and demanded that
4 Defendant rectify the problems associated with the actions detailed above and give
5 notice to all affected consumers of Defendant's intent to so act. A copy of the letter
6 is attached hereto as Exhibit C.

7 71. If Defendant fails to rectify or agree to rectify the problems associated
8 with the actions detailed above and give notice to all affected consumers within 30
9 days of the date of written notice pursuant to §1782 of the Act, Plaintiff will amend
10 this Complaint to add claims for actual, punitive and statutory damages, as
11 appropriate.

12 72. Defendant's conduct is fraudulent, wanton and malicious.

13 73. Pursuant to §1780(d) of the Act, attached hereto as Exhibit D is the
14 affidavit showing that this action has been commenced in the proper forum.

15 **PRAYER FOR RELIEF**

16 Wherefore, Plaintiff prays for a judgment:

- 17 A. Certifying the Class as requested herein;
18 B. Awarding restitution and disgorgement of Defendant's revenues to
19 Plaintiff and the proposed Class members;
20 C. Awarding injunctive relief as permitted by law or equity, including:
21 enjoining Defendant from continuing the unlawful practices as set forth herein;
22 D. Ordering Defendant to engage in a corrective advertising campaign;
23 E. Awarding attorneys' fees and costs; and
24 F. Providing such further relief as may be just and proper.

25 **DEMAND FOR JURY TRIAL**

26 Plaintiff hereby demands a trial of his claims by jury to the extent authorized
27 by law.

1 Dated: January 21, 2015

BONNETT, FAIRBOURN, FRIEDMAN
& BALINT, P.C.

/s/Patricia N. Syverson

2
3 Elaine A. Ryan (*To be Admitted Pro Hac Vice*)
Patricia N. Syverson (203111)
4 Lindsey M. Gomez-Gray (*To be Admitted Pro Hac*
5 *Vice*)
2325 E. Camelback Rd., Suite 300
6 Phoenix, AZ 85016
eryan@bffb.com
7 psyverson@bffb.com
lgomez-gray@bffb.com
8 Telephone: (602) 274-1100

9 BONNETT, FAIRBOURN, FRIEDMAN
& BALINT, P.C.

10 Manfred P. Muecke (222893)
600 W. Broadway, Suite 900
11 San Diego, California 92101
mmuecke@bffb.com
12 Telephone: (619) 756-7748

13 STEWART M. WELTMAN, LLC

14 Stewart M. Weltman (*To be Admitted Pro Hac*
Vice)
53 W. Jackson Suite 364
15 Chicago, IL 60604
sweltman@weltmanlawfirm.com
16 Telephone: (312) 588-5033

17 Attorneys for Plaintiff